Nuvectis Pharma (NVCT) FY 2025 Conference May 20, 2025 10:30 AM ET Speaker0 Okay. Good morning, everyone. Okay, good morning everyone and welcome back to the BioConnect Conference. My name is Joshua Corson and I am an Equity Research Associate here at H. C. Wainwright. So now I'd like to introduce our next presenter, Ron Benser, who is the CEO of Nivectis, which is developing its small molecule therapeutics, NXP 800 and NXP 900 in oncology. The floor is yours. Speaker1 Thank you very much. Thank you. I want ...